Moderna Inc [MRNA] stock prices are up 3.82% to $35.61 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MRNA shares have gain 15.02% over the last week, with a monthly amount glided 1.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on February 18, 2025, when Barclays downgraded its rating to a Equal Weight and also revised its price target to $45 from $111. Previously, Goldman downgraded its rating to Neutral on January 29, 2025, and dropped its price target to $51. On December 18, 2024, downgrade downgraded it’s rating to Hold. Berenberg initiated its recommendation with a Hold and recommended $42 as its price target on November 19, 2024. HSBC Securities upgraded its rating to Buy for this stock on November 18, 2024, but kept the price target unchanged to $58. In a note dated November 15, 2024, Wolfe Research initiated an Underperform rating and provided a target price of $40 on this stock.
The stock price of Moderna Inc [MRNA] has been fluctuating between $29.25 and $170.47 over the past year. Currently, Wall Street analysts expect the stock to reach $82.11 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $35.61 at the most recent close of the market. An investor can expect a potential return of 130.58% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
The Moderna Inc [NASDAQ:MRNA] reported sales of 3.24B for trailing twelve months, representing a drop of -65.54%. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -1.22%, Pretax Profit Margin comes in at -1.12%, and Net Profit Margin reading is -1.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.3 and Total Capital is -0.33. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.72 points at the first support level, and at 31.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.70, and for the 2nd resistance point, it is at 39.80.
Ratios To Look Out For
It’s worth pointing out that Moderna Inc [NASDAQ:MRNA]’s Current Ratio is 3.67. Further, the Quick Ratio stands at 3.62, while the Cash Ratio is 0.87. Considering the valuation of this stock, the price to sales ratio is 4.25, the price to book ratio is 1.26.
Transactions by insiders
Recent insider trading involved Bancel Stephane, Chief Executive Officer, that happened on Mar 03 ’25 when 0.16 million shares were purchased. Director, SAGAN PAUL completed a deal on Mar 03 ’25 to buy 31620.0 shares. Meanwhile, Chief Legal Officer Klinger Shannon Thyme sold 529.0 shares on Dec 09 ’24.
